Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 21177408)

1.

Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.

Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK.

Clin Cancer Res. 2011 Mar 15;17(6):1509-20. doi: 10.1158/1078-0432.CCR-10-1654. Epub 2010 Dec 21.

2.

Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.

McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, Reilly RM.

J Nucl Med. 2009 Aug;50(8):1340-8. doi: 10.2967/jnumed.109.062224. Epub 2009 Jul 17.

3.

Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.

Tang Y, Scollard D, Chen P, Wang J, Holloway C, Reilly RM.

Nucl Med Commun. 2005 May;26(5):427-32.

PMID:
15838425
4.

Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.

Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP.

Cancer Res. 2005 Feb 15;65(4):1471-8.

5.

18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.

McLarty K, Fasih A, Scollard DA, Done SJ, Vines DC, Green DE, Costantini DL, Reilly RM.

J Nucl Med. 2009 Nov;50(11):1848-56. doi: 10.2967/jnumed.109.067231. Epub 2009 Oct 16.

6.

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.

Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC.

Clin Cancer Res. 2009 Jul 15;15(14):4712-21. doi: 10.1158/1078-0432.CCR-08-2635. Epub 2009 Jul 7.

7.

(89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.

Oude Munnink TH, Korte MA, Nagengast WB, Timmer-Bosscha H, Schröder CP, Jong JR, Dongen GA, Jensen MR, Quadt C, Hooge MN, Vries EG.

Eur J Cancer. 2010 Feb;46(3):678-84. doi: 10.1016/j.ejca.2009.12.009. Epub 2009 Dec 24.

PMID:
20036116
8.

Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.

Razumienko EJ, Scollard DA, Reilly RM.

J Nucl Med. 2012 Dec;53(12):1943-50. doi: 10.2967/jnumed.112.106906. Epub 2012 Oct 24.

9.

On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.

Orlova A, Wållberg H, Stone-Elander S, Tolmachev V.

J Nucl Med. 2009 Mar;50(3):417-25. doi: 10.2967/jnumed.108.057919. Epub 2009 Feb 17.

10.

Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.

Paudyal P, Paudyal B, Hanaoka H, Oriuchi N, Iida Y, Yoshioka H, Tominaga H, Watanabe S, Watanabe S, Ishioka NS, Endo K.

Cancer Sci. 2010 Apr;101(4):1045-50. doi: 10.1111/j.1349-7006.2010.01480.x. Epub 2009 Dec 22.

PMID:
20219072
11.

In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.

Chen KT, Lee TW, Lo JM.

Nucl Med Biol. 2009 May;36(4):355-61. doi: 10.1016/j.nucmedbio.2009.01.006. Epub 2009 Mar 26.

PMID:
19423002
12.

Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model.

Kramer-Marek G, Gijsen M, Kiesewetter DO, Bennett R, Roxanis I, Zielinski R, Kong A, Capala J.

J Nucl Med. 2012 Apr;53(4):629-37. doi: 10.2967/jnumed.111.096685. Epub 2012 Mar 12.

13.

Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies.

Nayak TK, Bernardo M, Milenic DE, Choyke PL, Brechbiel MW.

Radiology. 2013 Apr;267(1):173-82. doi: 10.1148/radiol.12121021. Epub 2013 Jan 17.

14.

Impact of expression system on the function of the C6.5 diabody PET radiotracer.

Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Robinson MK.

Tumour Biol. 2012 Jun;33(3):617-27. doi: 10.1007/s13277-012-0361-z. Epub 2012 Mar 1.

15.

Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.

Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, Sevick-Muraca EM.

J Nucl Med. 2007 Sep;48(9):1501-10.

16.

In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.

Larbouret C, Robert B, Navarro-Teulon I, Thèzenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pèlegrin A, Azria D.

Clin Cancer Res. 2007 Jun 1;13(11):3356-62.

17.

Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.

Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Chiosis G, Lewis JS.

PLoS One. 2010 Jan 25;5(1):e8859. doi: 10.1371/journal.pone.0008859.

18.

Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.

Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA.

Mol Cancer Ther. 2012 Mar;11(3):752-62. doi: 10.1158/1535-7163.MCT-11-0742-T. Epub 2012 Jan 5.

20.

Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.

Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN.

J Nucl Med. 2009 Jun;50(6):974-81. doi: 10.2967/jnumed.108.060392. Epub 2009 May 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk